T1	Participants 458 533	randomized study of patients with gastric, pancreatic and colorectal cancer
T2	Participants 604 784	a randomized study of patients with resectable cancer of the colon and in nonrandomized consecutive studies of patients with malignant melanoma and stage IV carcinoma of the breast
T3	Participants 832 879	with advanced gastrointestinal cancer selective
